Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· July 20, 2026
Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer
View original at globenewswire.comTelix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer First patient dosed in Phase 3 LUTEON1 trial evaluating TLX250-Tx in relapsed or recurrent clear cell renal cell carcinoma (ccRCC).LUTEON is the first Phase 3 study of a CAIX2-targeted radiopharmaceutical therapy in ccRCC…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Dosing the first patient in LUTEON marks an important milestone; despite advances in care, outcomes remain poor for many ccRCC patients, underscoring the need for innovative therapeutic approaches, and the study will evaluate the safety, tolerability and efficacy of TLX250-Tx.
60% confidenceLUTEON represents the next stage in Telix's global clinical development of TLX250-Tx, which is designed to use the high prevalence of CAIX expression in ccRCC to deliver targeted radiation to tumor sites while limiting exposure to healthy tissue.
60% confidence
Cited in these Via News reports
- Cancer's two big bets: a personalised vaccine that held melanoma at bay, and AI that designs the drugs. Here is what is verified and what is not →
- Oncology's Next Wave Arrives on a Calendar: A Cancer Vaccine Readout on Oct. 24, an FDA Decision on Nov. 14 →
- Oncology's Q4 Decision Window: Three Dated Catalysts, One Already Delivered, and a Sector Splitting Between Cash-Rich and Cash-Careful →
- Oncology's Three Bets: New Drug Types, AI-Built Medicines and a $5.8 Billion Care Deal, and the Cash Behind One Closely Watched Drug →